Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Rawlins

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|May 15, 2023
Design of rigid protein-protein interaction inhibitors enables targeting of undruggable Mcl-1David Hargreaves, Rodrigo J Carbajo, Michael S Bodnarchuk, et al.
Bioorganic & Medicinal Chemistry Letters|June 26, 2003
1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases: highly potent 2,6-Difluorophenacyl analoguesRaj N Misra, Hai yun Xiao, David B Rawlins, et al.
Molecular Pharmacology|November 3, 2016
Structure-Activity Relationships of the Sustained Effects of Adenosine A2A Receptor Agonists Driven by Slow Dissociation KineticsJ Daniel Hothersall, Dong Guo, Sunil Sarda, et al.
Bioorganic & Medicinal Chemistry Letters|March 20, 2003
1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinasesRaj N Misra, David B Rawlins, Hai-yun Xiao, et al.
Nucleic Acids Research|January 29, 2021
Dynamics of the HD regulatory subdomain of PARP-1; substrate access and allostery in PARP activation and inhibitionTom E H Ogden, Ji-Chun Yang, Marianne Schimpl, et al.
ACS Chemical Biology|September 17, 2019
Rapid Identification of Novel Allosteric PRC2 InhibitorsJon A Read, Jonathan Tart, Philip B Rawlins, et al.
SLAS Discovery : Advancing Life Sciences R & D|October 30, 2016
Unified Software Solution for Efficient SPR Data Analysis in Drug ResearchGöran Dahl, Stephan Steigele, Per Hillertz, et al.
Archives of Toxicology|January 1, 2022
Pharmacological inhibition of MERTK induces in vivo retinal degeneration: a multimodal imaging ocular safety assessmentGregory Hamm, Gareth Maglennon, Beth Williamson, et al.
Pharmacology Research & Perspectives|June 4, 2015
LP-925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2David R Powell, Melinda G Smith, Deon D Doree, et al.
RSC Medicinal Chemistry|November 3, 2022
Fragment screening at AstraZeneca: developing the next generation biophysics fragment setSimon C C Lucas, Ulf Börjesson, Mark J Bostock, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Proceedings of the National Academy of Sciences of the United States of America|May 15, 2023
Design of rigid protein-protein interaction inhibitors enables targeting of undruggable Mcl-1David Hargreaves, Rodrigo J Carbajo, Michael S Bodnarchuk, et al.
Bioorganic & Medicinal Chemistry Letters|June 26, 2003
1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases: highly potent 2,6-Difluorophenacyl analoguesRaj N Misra, Hai yun Xiao, David B Rawlins, et al.
Molecular Pharmacology|November 3, 2016
Structure-Activity Relationships of the Sustained Effects of Adenosine A2A Receptor Agonists Driven by Slow Dissociation KineticsJ Daniel Hothersall, Dong Guo, Sunil Sarda, et al.
Bioorganic & Medicinal Chemistry Letters|March 20, 2003
1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinasesRaj N Misra, David B Rawlins, Hai-yun Xiao, et al.
Nucleic Acids Research|January 29, 2021
Dynamics of the HD regulatory subdomain of PARP-1; substrate access and allostery in PARP activation and inhibitionTom E H Ogden, Ji-Chun Yang, Marianne Schimpl, et al.
ACS Chemical Biology|September 17, 2019
Rapid Identification of Novel Allosteric PRC2 InhibitorsJon A Read, Jonathan Tart, Philip B Rawlins, et al.
SLAS Discovery : Advancing Life Sciences R & D|October 30, 2016
Unified Software Solution for Efficient SPR Data Analysis in Drug ResearchGöran Dahl, Stephan Steigele, Per Hillertz, et al.
Archives of Toxicology|January 1, 2022
Pharmacological inhibition of MERTK induces in vivo retinal degeneration: a multimodal imaging ocular safety assessmentGregory Hamm, Gareth Maglennon, Beth Williamson, et al.
Pharmacology Research & Perspectives|June 4, 2015
LP-925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2David R Powell, Melinda G Smith, Deon D Doree, et al.
RSC Medicinal Chemistry|November 3, 2022
Fragment screening at AstraZeneca: developing the next generation biophysics fragment setSimon C C Lucas, Ulf Börjesson, Mark J Bostock, et al.
Pageof 5